Jun 17, 2021

Cullgen Announces Prominent Publication by Cullgen Co-Founders Jian Jin and Yue Xiong in Nature Reviews Cancer

Jun 10, 2021

Cullgen Appoints Dr. Mark Deeg to Lead Clinical Development

Feb 25, 2021

Cullgen Closes $50 Million Series B Investment to Advance Targeted Protein Degraders and Novel E3 Ligands Platform

Oct 16, 2020

Cullgen Announces “Featured Article” Publication of First in Class TRK Protein Degraders in Journal of Medicinal Chemistry

Apr 7, 2020

Cullgen Announces Publication of Small Molecule BRAF Protein Degraders in Journal of Medicinal Chemistry

Apr 10, 2019

Cullgen Receives $16 Million Series A Investment to Advance Pipeline of Targeted Protein Degraders

Jul 18, 2018

Cullgen Announces Expanded Scientific Advisory Board

Jul 18, 2018

Apr 2, 2018

Cullgen Announces ALK PROTACs Publication by Its Co-founders in the European Journal of Medicinal Chemistry

Mar 1, 2018

Cullgen Announces Series Seed Financing

Google Analytics Alternative